# Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma

> **NCT07261163** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 37 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Obinutuzumab
- **DRUG:** Lenalidomide
- **OTHER:** CAR-T Cell Therapy

## Key facts

- **NCT ID:** NCT07261163
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-20
- **Primary completion:** 2027-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07261163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07261163, "Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT07261163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*